메뉴 건너뛰기




Volumn 31, Issue 3, 2007, Pages 703-712

Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia

Author keywords

Antipsychotics; Quality of life; Schizophrenia; Subjective well being

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

EID: 33947500447     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.01.004     Document Type: Article
Times cited : (43)

References (42)
  • 3
    • 0001072895 scopus 로고
    • The use of confidence or fiducial limits illustrated in the case of the binomial
    • Clopper C., and Pearson S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26 (1934) 404-413
    • (1934) Biometrika , vol.26 , pp. 404-413
    • Clopper, C.1    Pearson, S.2
  • 4
    • 0034702175 scopus 로고    scopus 로고
    • Randomized, controlled trials, observational studies, and the hierarchy of research designs
    • Concato J., Shah N., and Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342 (2000) 1887-1892
    • (2000) N Engl J Med , vol.342 , pp. 1887-1892
    • Concato, J.1    Shah, N.2    Horwitz, R.I.3
  • 5
    • 0033862429 scopus 로고    scopus 로고
    • Quality of life in schizophrenia: a comparison of instruments
    • for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia
    • Cramer J.A., et al., for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Quality of life in schizophrenia: a comparison of instruments. Schizophr Bull 26 (2000) 659-666
    • (2000) Schizophr Bull , vol.26 , pp. 659-666
    • Cramer, J.A.1
  • 6
    • 0036307453 scopus 로고    scopus 로고
    • Relapse and rehospitalization rates in patients with schizophrenia: effects of second generation antipsychotics
    • Csernansky J.G., and Schuchart E.K. Relapse and rehospitalization rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16 (2002) 473-484
    • (2002) CNS Drugs , vol.16 , pp. 473-484
    • Csernansky, J.G.1    Schuchart, E.K.2
  • 7
    • 0035987323 scopus 로고    scopus 로고
    • Psychometric properties of the Subjective Well-being under Neuroleptics scale and the subjective deficit syndrome scale
    • de Haan L., Weisfelt M., Dingemans P.M.A.J., Linszen D.H., and Wouters L. Psychometric properties of the Subjective Well-being under Neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology 162 (2002) 24-28
    • (2002) Psychopharmacology , vol.162 , pp. 24-28
    • de Haan, L.1    Weisfelt, M.2    Dingemans, P.M.A.J.3    Linszen, D.H.4    Wouters, L.5
  • 8
    • 23944442440 scopus 로고    scopus 로고
    • Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the International Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
    • Dossenbach M., Arango-Davila C., Silva Ibarra H., Landa E., Aguila J., Caro O., et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the International Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 66 (2005) 1021-1030
    • (2005) J Clin Psychiatry , vol.66 , pp. 1021-1030
    • Dossenbach, M.1    Arango-Davila, C.2    Silva Ibarra, H.3    Landa, E.4    Aguila, J.5    Caro, O.6
  • 9
    • 21244486283 scopus 로고    scopus 로고
    • Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study
    • on behalf of the SOHO Study Group
    • Gasquet I., et al., on behalf of the SOHO Study Group. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol 20 (2005) 199-205
    • (2005) Int Clin Psychopharmacol , vol.20 , pp. 199-205
    • Gasquet, I.1
  • 10
    • 0037410287 scopus 로고    scopus 로고
    • Olanzapine vs. risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand
    • Gureje O., Miles W., Keks N., Grainger D., Lambert T., McGrath J., et al. Olanzapine vs. risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 61 (2003) 303-314
    • (2003) Schizophr Res , vol.61 , pp. 303-314
    • Gureje, O.1    Miles, W.2    Keks, N.3    Grainger, D.4    Lambert, T.5    McGrath, J.6
  • 11
    • 0031905314 scopus 로고    scopus 로고
    • Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial
    • Hamilton S.H., Revicki D.A., Genduso L.A., and Beasley C.M. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18 1 (1998) 41-49
    • (1998) Neuropsychopharmacology , vol.18 , Issue.1 , pp. 41-49
    • Hamilton, S.H.1    Revicki, D.A.2    Genduso, L.A.3    Beasley, C.M.4
  • 12
    • 0033846290 scopus 로고    scopus 로고
    • Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample
    • Hamilton S.H., Edgell E.T., Revicki D.A., and Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 15 5 (2000) 245-255
    • (2000) Int Clin Psychopharmacol , vol.15 , Issue.5 , pp. 245-255
    • Hamilton, S.H.1    Edgell, E.T.2    Revicki, D.A.3    Breier, A.4
  • 13
    • 14844309335 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study
    • Haro J.M., Edgell E.T., Novick D., Alonso J., Kennedy L., Jones P.B., et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 111 (2005) 220-231
    • (2005) Acta Psychiatr Scand , vol.111 , pp. 220-231
    • Haro, J.M.1    Edgell, E.T.2    Novick, D.3    Alonso, J.4    Kennedy, L.5    Jones, P.B.6
  • 14
    • 32644448441 scopus 로고    scopus 로고
    • Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia
    • SOHO Advisory Board
    • Haro J.M., Novick D., Belger M., Jones P.B., and SOHO Advisory Board. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry 21 (2006) 41-47
    • (2006) Eur Psychiatry , vol.21 , pp. 41-47
    • Haro, J.M.1    Novick, D.2    Belger, M.3    Jones, P.B.4
  • 15
    • 33846558834 scopus 로고    scopus 로고
    • Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized study results
    • SOHO Study Group
    • Haro J.M., Suarez D., Novick D., Brown J., Usall J., Naber D., and SOHO Study Group. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized study results. Eur Neuropsychopharmacol 7 (2007) 235-244
    • (2007) Eur Neuropsychopharmacol , vol.7 , pp. 235-244
    • Haro, J.M.1    Suarez, D.2    Novick, D.3    Brown, J.4    Usall, J.5    Naber, D.6
  • 16
    • 0021154534 scopus 로고
    • The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome
    • Heinrichs D.H., Hanlon T.E., and Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10 (1984) 388-398
    • (1984) Schizophr Bull , vol.10 , pp. 388-398
    • Heinrichs, D.H.1    Hanlon, T.E.2    Carpenter, W.T.3
  • 17
    • 4444254472 scopus 로고    scopus 로고
    • Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects
    • Hofer A., Kemmler G., Eder U., Edlinger M., Hummer M., and Fleischhacker W.W. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 65 7 (2004) 932-939
    • (2004) J Clin Psychiatry , vol.65 , Issue.7 , pp. 932-939
    • Hofer, A.1    Kemmler, G.2    Eder, U.3    Edlinger, M.4    Hummer, M.5    Fleischhacker, W.W.6
  • 18
    • 24944456746 scopus 로고    scopus 로고
    • Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects
    • Hofer A., Baumgartner S., Edlinger M., Hummer M., Kemmler G., Rettenbacher M.A., et al. Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry 20 (2005) 386-394
    • (2005) Eur Psychiatry , vol.20 , pp. 386-394
    • Hofer, A.1    Baumgartner, S.2    Edlinger, M.3    Hummer, M.4    Kemmler, G.5    Rettenbacher, M.A.6
  • 19
    • 0035987326 scopus 로고    scopus 로고
    • Subjective well-being and quality of life under atypical antipsychotic treatment
    • Karow A., and Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 162 (2002) 3-10
    • (2002) Psychopharmacology , vol.162 , pp. 3-10
    • Karow, A.1    Naber, D.2
  • 20
    • 3242788666 scopus 로고    scopus 로고
    • Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics
    • Kilian R., Dietrich S., Toumi M., and Angermeyer M.C. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. Acta Psychiatr Scand 110 (2004) 108-118
    • (2004) Acta Psychiatr Scand , vol.110 , pp. 108-118
    • Kilian, R.1    Dietrich, S.2    Toumi, M.3    Angermeyer, M.C.4
  • 21
    • 14044249439 scopus 로고    scopus 로고
    • A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being
    • Kluge M., Wehmeier P.M., Dittmann R.W., Langer F., Czekalla J., Lehmann M., et al. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 38 1 (2005) 6-12
    • (2005) Pharmacopsychiatry , vol.38 , Issue.1 , pp. 6-12
    • Kluge, M.1    Wehmeier, P.M.2    Dittmann, R.W.3    Langer, F.4    Czekalla, J.5    Lehmann, M.6
  • 22
    • 33845658698 scopus 로고    scopus 로고
    • Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia
    • Lambert M., Schimmelmann B.G., Naber D., Schacht A., Karow A., Wagner T., et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 67 (2006) 1690-1697
    • (2006) J Clin Psychiatry , vol.67 , pp. 1690-1697
    • Lambert, M.1    Schimmelmann, B.G.2    Naber, D.3    Schacht, A.4    Karow, A.5    Wagner, T.6
  • 23
    • 25144456112 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    • for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
    • Lieberman J.A., et al., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
    • (2005) N Engl J Med , vol.353 , pp. 1209-1223
    • Lieberman, J.A.1
  • 24
    • 33645026406 scopus 로고    scopus 로고
    • Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study
    • Mayoral F., Montejo A., Bousono M., Gonzalez-Torres M., Olivares J., Ros S., et al. Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study. Actas Esp Psiquiatr 34 (2006) 7-15
    • (2006) Actas Esp Psiquiatr , vol.34 , pp. 7-15
    • Mayoral, F.1    Montejo, A.2    Bousono, M.3    Gonzalez-Torres, M.4    Olivares, J.5    Ros, S.6
  • 25
    • 0037674667 scopus 로고    scopus 로고
    • Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study
    • Montes J.M., Ciudad A., Gascón J., and Gómez J.C. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 7 4 (2003) 667-674
    • (2003) Prog Neuropsychopharmacol Biol Psychiatry , vol.7 , Issue.4 , pp. 667-674
    • Montes, J.M.1    Ciudad, A.2    Gascón, J.3    Gómez, J.C.4
  • 26
    • 0029558065 scopus 로고
    • A self-rating to measure subjective effects of neuroleptic drugs. Relationships to objective psychopathology, quality of life, compliance and other clinical variables
    • Naber D. A self-rating to measure subjective effects of neuroleptic drugs. Relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 10 Supplement 3 (1995) 133-138
    • (1995) Int Clin Psychopharmacol , vol.10 , Issue.SUPPL. 3 , pp. 133-138
    • Naber, D.1
  • 27
    • 0035972707 scopus 로고    scopus 로고
    • Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs
    • Naber D., Moritz S., Lambert M., Rajonk F., Holzbach R., Mass R., et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 50 (2001) 79-88
    • (2001) Schizophr Res , vol.50 , pp. 79-88
    • Naber, D.1    Moritz, S.2    Lambert, M.3    Rajonk, F.4    Holzbach, R.5    Mass, R.6
  • 28
    • 20344392860 scopus 로고    scopus 로고
    • Subjective well-being under neuroleptic treatment and its relevance for compliance
    • Naber D., Karow A., and Lambert M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand 111 Supplement 427 (2005) 29-34
    • (2005) Acta Psychiatr Scand , vol.111 , Issue.SUPPL. 427 , pp. 29-34
    • Naber, D.1    Karow, A.2    Lambert, M.3
  • 29
    • 20044376675 scopus 로고    scopus 로고
    • Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcomes in patients with schizophrenia
    • Naber D., Riedel M., Klimke A., Vorbach E.U., Lambert M., Kühn K.U., et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcomes in patients with schizophrenia. Acta Psychiatr Scand 111 (2005) 106-115
    • (2005) Acta Psychiatr Scand , vol.111 , pp. 106-115
    • Naber, D.1    Riedel, M.2    Klimke, A.3    Vorbach, E.U.4    Lambert, M.5    Kühn, K.U.6
  • 30
    • 0034095251 scopus 로고    scopus 로고
    • Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol: the Canadian Collaborative Group for Research in Schizophrenia
    • Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol: the Canadian Collaborative Group for Research in Schizophrenia. Arch Gen Psychiatry 57 (2000) 249-258
    • (2000) Arch Gen Psychiatry , vol.57 , pp. 249-258
    • Purdon, S.E.1    Jones, B.D.2    Stip, E.3    Labelle, A.4    Addington, D.5    David, S.R.6
  • 31
    • 1542641522 scopus 로고    scopus 로고
    • Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders. Quality of life and clinical outcomes of a randomized clinical trial
    • Revicki D.A., Genduso L.A., Hamilton S.H., Ganoczy D., and Beasley C.M. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders. Quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 8 (1999) 417-426
    • (1999) Qual Life Res , vol.8 , pp. 417-426
    • Revicki, D.A.1    Genduso, L.A.2    Hamilton, S.H.3    Ganoczy, D.4    Beasley, C.M.5
  • 32
    • 8744294887 scopus 로고    scopus 로고
    • Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice. A naturalistic comparative study
    • Ritsner M., Gibel A., Perelroyzen G., Kurs R., Jabarin M., and Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice. A naturalistic comparative study. J Clin Psychopharmacol 24 6 (2004) 582-591
    • (2004) J Clin Psychopharmacol , vol.24 , Issue.6 , pp. 582-591
    • Ritsner, M.1    Gibel, A.2    Perelroyzen, G.3    Kurs, R.4    Jabarin, M.5    Ratner, Y.6
  • 33
    • 22744457230 scopus 로고    scopus 로고
    • Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics
    • Silva de Lima M., de Jesus Mari J., Breier A., Costa A.M., Pondé de Sena E., and Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J Clin Psychiatry 66 7 (2005) 831-838
    • (2005) J Clin Psychiatry , vol.66 , Issue.7 , pp. 831-838
    • Silva de Lima, M.1    de Jesus Mari, J.2    Breier, A.3    Costa, A.M.4    Pondé de Sena, E.5    Hotopf, M.6
  • 34
    • 0037299062 scopus 로고    scopus 로고
    • Which neuroleptic would psychiatrists take for themselves or their relatives?
    • Steinert T. Which neuroleptic would psychiatrists take for themselves or their relatives?. Eur Psychiatry 18 (2003) 40-41
    • (2003) Eur Psychiatry , vol.18 , pp. 40-41
    • Steinert, T.1
  • 35
    • 0030993030 scopus 로고    scopus 로고
    • Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
    • Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154 4 (1997) 457-465
    • (1997) Am J Psychiatry , vol.154 , Issue.4 , pp. 457-465
    • Tollefson, G.D.1    Beasley, C.M.2    Tran, P.V.3    Street, J.S.4    Krueger, J.A.5    Tamura, R.N.6
  • 36
    • 0030770872 scopus 로고    scopus 로고
    • Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
    • Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17 (1997) 40-418
    • (1997) J Clin Psychopharmacol , vol.17 , pp. 40-418
    • Tran, P.V.1    Hamilton, S.H.2    Kuntz, A.J.3    Potvin, J.H.4    Andersen, S.W.5    Beasley, C.6
  • 37
    • 0034674458 scopus 로고    scopus 로고
    • Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life
    • Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S., and Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 43 (2000) 135-145
    • (2000) Schizophr Res , vol.43 , pp. 135-145
    • Voruganti, L.1    Cortese, L.2    Oyewumi, L.3    Cernovsky, Z.4    Zirul, S.5    Awad, A.6
  • 38
    • 14644417140 scopus 로고    scopus 로고
    • Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation
    • Wehmeier P.M., Gebhardt S., Schmidtke J., Remschmidt H., Hebebrand J., and Theisen F.M. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res 133 (2005) 273-276
    • (2005) Psychiatry Res , vol.133 , pp. 273-276
    • Wehmeier, P.M.1    Gebhardt, S.2    Schmidtke, J.3    Remschmidt, H.4    Hebebrand, J.5    Theisen, F.M.6
  • 39
    • 33947534118 scopus 로고    scopus 로고
    • Wehmeier, PM, Kluge M, Schacht A, Helsberg K, Schreiber W (in press). Correlation of physician and patient rated quality of life during antipsychotic treatment in out-patients with schizophrenia. Schizophr Res.
  • 40
    • 10644233003 scopus 로고    scopus 로고
    • Systematic comparison of subjective and objective measures of quality of life at 4-year follow-up subsequent to a first episode of psychosis
    • Whitty P., Browne S., Clarke M., McTigue O., Waddington J., Kinsella T., et al. Systematic comparison of subjective and objective measures of quality of life at 4-year follow-up subsequent to a first episode of psychosis. J Nerv Ment Dis 192 12 (2004) 805-809
    • (2004) J Nerv Ment Dis , vol.192 , Issue.12 , pp. 805-809
    • Whitty, P.1    Browne, S.2    Clarke, M.3    McTigue, O.4    Waddington, J.5    Kinsella, T.6
  • 41
    • 4444358290 scopus 로고    scopus 로고
    • Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients
    • Zhang P.L., Santos J.M., Newcomer J., Pelfrey B.A., Johnson M.C., and de Erausquin G.A. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res 71 (2004) 137-144
    • (2004) Schizophr Res , vol.71 , pp. 137-144
    • Zhang, P.L.1    Santos, J.M.2    Newcomer, J.3    Pelfrey, B.A.4    Johnson, M.C.5    de Erausquin, G.A.6
  • 42
    • 28644433423 scopus 로고    scopus 로고
    • Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
    • Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 187 (2005) 537-543
    • (2005) Br J Psychiatry , vol.187 , pp. 537-543
    • Zipursky, R.B.1    Gu, H.2    Green, A.I.3    Perkins, D.O.4    Tohen, M.F.5    McEvoy, J.P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.